Bio-Techne Corp Common Stock TECH
i
Market dataready · fetched 2026-11-12T01:46:53.389Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:28:26.420270998Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T01:46:53.025411+00:00
Bio-Techne Corp Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 74.05 | 13.8% | 2.6% | 47.11 | 240.2% | 37.2% |
| 25Δ | 73.74 | 14.7% | 2.4% | 49.67 | 220.6% | 33.8% |
| 30Δ | 73.43 | 15.6% | 2.2% | 52.24 | 201.0% | 30.4% |
| 35Δ | 73.11 | 16.5% | 2.1% | 54.81 | 181.4% | 27.1% |
| 40Δ | 72.80 | 17.4% | 1.9% | 57.38 | 161.8% | 23.7% |
| 45Δ | 72.49 | 18.2% | 1.7% | 59.95 | 142.2% | 20.3% |
| 50Δ | 72.18 | 19.1% | 1.6% | 62.52 | 122.5% | 16.9% |
| 55Δ | 71.86 | 20.0% | 1.4% | 65.09 | 102.9% | 13.6% |
| 60Δ | 71.55 | 20.9% | 1.2% | 67.66 | 83.3% | 10.2% |
| 65Δ | 71.24 | 21.8% | 1.1% | 70.23 | 63.7% | 6.8% |
| 70Δ | 70.93 | 22.7% | 0.9% | 72.80 | 44.1% | 3.4% |
| 75Δ | 70.61 | 23.6% | 0.7% | 75.28 | 28.6% | 0.5% |
| 80Δ | 70.30 | 24.5% | 0.6% | 77.28 | 38.3% | 0.5% |
20Δ
- Pseudo strike
- 74.05
- IV
- 13.8%
- B/E move
- 2.6%
- Pseudo strike
- 47.11
- IV
- 240.2%
- B/E move
- 37.2%
25Δ
- Pseudo strike
- 73.74
- IV
- 14.7%
- B/E move
- 2.4%
- Pseudo strike
- 49.67
- IV
- 220.6%
- B/E move
- 33.8%
30Δ
- Pseudo strike
- 73.43
- IV
- 15.6%
- B/E move
- 2.2%
- Pseudo strike
- 52.24
- IV
- 201.0%
- B/E move
- 30.4%
35Δ
- Pseudo strike
- 73.11
- IV
- 16.5%
- B/E move
- 2.1%
- Pseudo strike
- 54.81
- IV
- 181.4%
- B/E move
- 27.1%
40Δ
- Pseudo strike
- 72.80
- IV
- 17.4%
- B/E move
- 1.9%
- Pseudo strike
- 57.38
- IV
- 161.8%
- B/E move
- 23.7%
45Δ
- Pseudo strike
- 72.49
- IV
- 18.2%
- B/E move
- 1.7%
- Pseudo strike
- 59.95
- IV
- 142.2%
- B/E move
- 20.3%
50Δ
- Pseudo strike
- 72.18
- IV
- 19.1%
- B/E move
- 1.6%
- Pseudo strike
- 62.52
- IV
- 122.5%
- B/E move
- 16.9%
55Δ
- Pseudo strike
- 71.86
- IV
- 20.0%
- B/E move
- 1.4%
- Pseudo strike
- 65.09
- IV
- 102.9%
- B/E move
- 13.6%
60Δ
- Pseudo strike
- 71.55
- IV
- 20.9%
- B/E move
- 1.2%
- Pseudo strike
- 67.66
- IV
- 83.3%
- B/E move
- 10.2%
65Δ
- Pseudo strike
- 71.24
- IV
- 21.8%
- B/E move
- 1.1%
- Pseudo strike
- 70.23
- IV
- 63.7%
- B/E move
- 6.8%
70Δ
- Pseudo strike
- 70.93
- IV
- 22.7%
- B/E move
- 0.9%
- Pseudo strike
- 72.80
- IV
- 44.1%
- B/E move
- 3.4%
75Δ
- Pseudo strike
- 70.61
- IV
- 23.6%
- B/E move
- 0.7%
- Pseudo strike
- 75.28
- IV
- 28.6%
- B/E move
- 0.5%
80Δ
- Pseudo strike
- 70.30
- IV
- 24.5%
- B/E move
- 0.6%
- Pseudo strike
- 77.28
- IV
- 38.3%
- B/E move
- 0.5%
Options history
No recorded observations
Biotechnology
TECX
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients…
More →TENX
Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the…
More →TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →TNGX
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies.…
More →TNXP
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
More →TNYA
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology firm that is revolutionizing the treatment of heart disease through its proprietary engineered heart cell…
More →